eb_2019_royovel.PNG

 Ergomed plc, a company focused on providing specialised services to the pharmaceutical industry, today announces the appointment of Roy Ovel as Chief Commercial Officer with immediate effect.

© 123rf.com/thelightwriter

The European Medicines Agency has granted conditional approval for bluebird bio NV’s gene therapy Zynteglo (LentiGlobin BB305) to treat the rare disease transfusion-dependent ?-thalassemia at its first meeting in Amsterdam.